Nevertheless, despite the well-recognized clinical significance of claudin-4 in ovarian cancer (2, 17–19, 23), the molecular mechanisms by which it promotes the development of therapy resistance, as well as its association with genomic instability, remain poorly understood. Here, CLDN4 is linked to ovarian cancer.